Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 4359457
SERIAL NO

06186735

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A tumor suppressive composition active against lymphoma consisting of an injection of hybrid protein anti Thy 1.2 monoclonal antibody-ricin and hyperosmotic lactose. The inoculation i.v. of murine tissues in vivo by lymphoma is made at -20 to -25 days and the tumor suppressant composition is used i.v. at Day 1 in an amount of 1-3 .mu.g of anti Thy monoclonal antibody-ricin together with sufficient hyperosmotic lactose to raise the lactose level to 20-30 mM. The broad purpose of this invention is to modify the receptor specificity of a potent toxin such as ricin by coupling it with a monoclonal antibody directed at a specific tumor or differentiation antigen. The object here is to use the reagent to selectively kill tumor cells without affecting normal cells.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
HEALTH AND HUMAN SERVICES UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OFROCKVILLE MD 20852

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Neville, Jr David M 9624 Parkwood Dr., Bethesda, MD 20014 11 265
Youle, Richard J 9629 Old Spring Rd., Kensington, MD 20795 26 452

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation